70 likes | 226 Views
A Double-blind, Placebo-controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia (MMM 500). Wilcock G., Möbius H.J., and Stöffler A. on behalf of the MMM 500 group Int Clin Psychopharmacol 2002, 17(6):297-305. Study Design. No. of patients N = 579
E N D
A Double-blind, Placebo-controlled Multicentre Study of Memantine in Mild to Moderate Vascular Dementia (MMM 500) Wilcock G., Möbius H.J., and Stöffler A. on behalf of the MMM 500 group Int Clin Psychopharmacol 2002, 17(6):297-305
Study Design No. of patients N = 579 Design Double-blind, randomized, placebo- controlled, multicenter study Diagnosis Probable VaD (HIS score 4, DSM-III-R, NINDS-AIREN) Age 54 years (mean 77) Severity MMSE 10 - 22 (mean 17.6) Dose; duration 20 mg memantine/day; 28 weeks Primary efficacy Cognition: ADAS-cogparameters Global: CGI-C Secondary efficacy MMSE, GBS, NOSGER, parameters Wilcock et al., Int Clin Psychopharmacol 2002
Disposition of Patients Patients screenedN = 840 Screen failuresN = 261 (31%) Patients randomizedN = 579 PlaceboN = 284 (49%) MemantineN = 295 (51%) CompletedN = 226(80%) WithdrewN = 58(20%) CompletedN = 238(81%) WithdrewN = 57(19%) Wilcock et al., Int Clin Psychopharmacol 2002
24 25 26 27 28 29 * Memantine (20 mg/day) Placebo 0 12 28 Significant Benefit of Memantine on Cognition (ADAS-cog) ITT, LOCF ADAS-cog total score ADAS-cog total score Worsening Week *p < 0.05 versus placebo Wilcock et al., Int Clin Psychopharmacol 2002
-2 0 2 4 * Memantine (20 mg/day) Placebo 0 12 28 Significant Benefit of Memantine on Cognition (ADAS-cog) ITT, LOCF Mean change from baseline Improvement ADAS-cog score difference Worsening Week *p < 0.05 versus placebo Wilcock et al., Int Clin Psychopharmacol 2002
Good Safety and Tolerability of Memantine Adverse events in mild to moderate VaD (MMM500) Memantine Placebo No. of patients 295 (100%) 284 (100%) No. of patients with AEs 226 (77%) 212 (75%) Dizziness 33 (11%) 23 (8%) Inflicted injury 17 (6%) 30 (11%) Confusion 22 (7%) 21 (7%) Constipation 30 (10%) 12 (4%) Bronchitis 20 (7%) 20 (7%) Headache 21 (7%) 19 (7%) Fall 18 (6%) 21 (7%) Coughing 20 (7%) 15 (5%) Agitation 11 (4%) 23 (8%) Wilcock et al., Int Clin Psychopharmacol 2002
Summary • Significant cognitive benefit for memantine treated patients in mild to moderate vascular dementia • Good safety and tolerability of memantine Wilcock et al., Int Clin Psychopharmacol 2002